XRTX · XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company developing therapies for gout and kidney diseases, has priced a US$5 million public offering to bolster its capital position. The offering includes 2,659,574 common shares or pre-funded warrant equivalents at US$1.88 per unit, generating gross proceeds of US$5 million before deducting placement agent fees and expenses payable to E.F. Hutton & Co., the exclusive agent. Pre-funded warrants feature a nominal exercise price of US$0.0001 per share, are immediately exercisable, and terminate once fully exercised, providing flexibility to investors. Closure is targeted for on or about May 15, 2026, contingent on standard conditions including necessary regulatory approvals, notably from the TSX Venture Exchange. The securities are offered under an SEC-effective Form F-1 registration statement (File No. 333-290512), with a final prospectus to be filed. This financing supports XORTX's pipeline, including lead XRx-026 for gout, XRx-008 for ADPKD, XRx-101 for acute kidney injury, XRx-225 for diabetic nephropathy, and the recently acquired VB4-P5 program, all targeting purine metabolism and xanthine oxidase inhibition to address unmet needs in kidney-related diseases.